Virchows Archiv A

, Volume 414, Issue 4, pp 345–353 | Cite as

Immunocytochemical identification of osteogenic bone tumors by osteonectin antibodies

  • G. Jundt
  • A. Schulz
  • K. -H. Berghäuser
  • L. W. Fisher
  • P. Gehron-Robey
  • J. D. Termine
Article

Summary

18 bone-forming tumours and tumour-like lesions were investigated immunocytochemically for the presence of osteonectin. A group of non-bone-forming skeletal tumours (five cartilage-forming tumours, four Ewing sarcomas and five extraskeletal sarcomas) served as controls. The studies showed that osteonectin antibodies react reliably with benign and malignant bone-forming tumours (two cases of fibrous dysplasia, three osteoid osteomas, 13 osteosarcomas). This finding was supported by protein blot studies. Osteonectin is formed by cells which do not yet possess the morphological phenotype of osteoblasts and may be regarded as a “differentiation marker” of the osteoblastic lineage. Only chondroid bone (tissue in which chondrocytes were surrounded by osteoid matrix containing type I and type II collagen) showed a positive reaction. All other primary skeletal tumours and extraskeletal soft tissue tumours were completely negative.

Key words

Bone tumors Osteosarcoma Osteonectin Immunocytochemistry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beresford WA (1981) Chondroid bone, secondary cartilage and metaplasia. Urban und Schwarzenberg, Baltimore MünchenGoogle Scholar
  2. Bianco P, Silvestrini G, Termine JD, Bonucci E (1988) Immunohistochemical localization of osteonectin in developing human and calf bone using monoclonal antibodies. Calcif Tissue Int 43:155–161Google Scholar
  3. Brozman M (1978) Immunohistochemical analysis of formaldehyde-and trypsin- or pepsin-treated material. Acta Histochem 63:251–260Google Scholar
  4. Bruland O, Fodstad O, Fundernd S, Pihl A (1986) New monoclonal antibodies specific for human sarcomas. Int J Cancer 38:27–31Google Scholar
  5. Dahlin DC, Unni KK (1986) Bone Tumors. 4th ed., CC Thomas, SpringfieldGoogle Scholar
  6. Dziadek M, Paulsson M, Aumailley M, Timpl R (1986) Purification and tissue distribution of a small protein (BM 40) extracted from a basement membrane tumor. Eur J Biochem 161:455–464Google Scholar
  7. Findlay DM, Fisher LW, McQuillan CI, Termine JD, Young MF (1988) Isolation of the osteonectin gene: Evidence that a variable region of the osteonectin molecule is encoded within one exon. Biochemistry 27:1483–1489Google Scholar
  8. Fisher LW, Termine JD (1985) Noncollagenous proteins influencing the local mechanisms of calcification. Clin Orthop Rel Res 200:362–385Google Scholar
  9. Friedenstein AJ (1973) Determined and inducible osteogenic precursor cells. In: Hard Tissue Growth, Repair, and Mineralization (CIBA Foundation Symposium), Blackwell, London, pp 169–185Google Scholar
  10. Gehron Robey P, Termine JD (1985) Human bone cells in vitro. Calcif Tissue Int 37:453–460Google Scholar
  11. Gehron Robey P, Fisher LW, Stubbs JT, Termine JD (1987) Biosynthesis of osteonectin and a small proteoglycan (PG-II) by connective tissue cells in vitro. In: Development and Diseases of Cartilage and Bone Matrix, AR Liss Inc. New York, pp 115–125Google Scholar
  12. Gravanis MB, Giansanti JS (1971) Benign chondroblastoma. Report of four cases with a discussion of the presence of ossification. Am J Clin Pathol 55:624–631Google Scholar
  13. Hsu SM, Raine L, Fanger H (1984) Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580Google Scholar
  14. Huvos AG (1979) Bone Tumors. WB Saunders Comp. Philadelphia Toronto LondonGoogle Scholar
  15. Jundt G, Berghäuser K-H, Termine JD, Schulz A (1987) Osteonectin- a differentiation marker of bone cells. Cell Tiss Res 248:409–415Google Scholar
  16. Mason IJ, Taylor A, Williams JG, Sage H, Hogan BLM (1986) Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell “culture shock” glycoprotein of M. 43.000. EMBO J 5:1565–1472Google Scholar
  17. Otsuka K, Yao K-L, Wasi S, Tung PS, Aubin JE, Sodek J, Termine JD (1984) Biosynthesis of osteonectin by fetal porcine calvarial cells in vitro. J Biol Chem 259:9805–9812Google Scholar
  18. Remberger K, Gay S (1977) Immunohistochemical demonstration of different collagen types in the normal epiphyseal plate and in benign and malignant tumors of bone and cartilage. Z Krebsforsch 90:95–106Google Scholar
  19. Roessner A, Voss B, Rauterberg J, Immenkamp M, Gundermann E (1983) Biologic characterization of human bone tumors. J Cancer Res Clin Oncol 106:234–239Google Scholar
  20. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Metha B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230Google Scholar
  21. Sage H, Tupper J, Bramson R (1986) Endothelial cell injury in vitro is associated with increased secretion of an M. 43.000 glycoprotein ligand. J Cell Physiol 127:373–387Google Scholar
  22. Schajowicz F (1981) Tumors and tumorlike lesions of bone and joints. Springer-Verlag, Berlin Heidelberg New YorkGoogle Scholar
  23. Schulz A, Jundt G, Berghäuser K-H, Gehron Robey P, Termine JD (1988) Immunohistochemical study of Osteonectin in various types of osteosarcoma. Am J Pathol 132:233–238Google Scholar
  24. Stenner DD, Tracy RP, Riggs BL, Mann KG (1986) Human platelets contain and secrete osteonectin, a major protein of mineralized bone. PNAS 83:6892–6896Google Scholar
  25. Sternberger LA (1979) Immunocytochemistry 2nd ed. John Wiley & Sons, New YorkGoogle Scholar
  26. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR (1981) Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26:99–105Google Scholar
  27. Tung PS, Domenicucci C, Wasi S, Sodek J (1985) Specific immunohistochemical localization of osteonectin and collagen types I and III in fetal and adult porcine dental tissues. J Histochem Cytochem 33:531–540Google Scholar
  28. van Noorden S, Polak JM (1983) Immunocytochemistry today- techniques and practice. In: Polak JM, van Noorden D (eds) Immunocytochemistry. Wright PSG, Bristol London Boston pp 11–42Google Scholar
  29. von der Mark K (1981) Localization of collagen types in tissues. Int Rev Connect Tissue Res 9:265–324Google Scholar
  30. Whitson SW, Harrison W, Dunlap MK, Bowers jr DE, Fisher LW, Robey PG, Termine JD (1984) Fetal bovine bone cells synthesize bone-specific matrix proteins. J Cell Biol 99:607–614Google Scholar
  31. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Ettmann R, Göbel U, Havers W, Henze G, Hinderfeld C, Höocker P, Jobke A, Jürgens H, Kabisch H, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, Wüst G, Landbeck G (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German Austrian study. J Clin Oncol 2:614–624Google Scholar
  32. Young MF, Bolander ME, Day AA, Ramis CI, Gehron Robey P, Yamada Y, Termine JD (1986) Osteonectin mRNA: distribution in normal and transformed cells. Nucleic Acids Research 14:4483–4497Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • G. Jundt
    • 1
  • A. Schulz
    • 1
  • K. -H. Berghäuser
    • 1
  • L. W. Fisher
    • 2
  • P. Gehron-Robey
    • 2
  • J. D. Termine
    • 2
  1. 1.Institute of PathologyUniversity of GiessenGiessenFRG
  2. 2.National Institute of HealthBethesdaUSA

Personalised recommendations